NEUROCRINE
PharmaNEUROCRINE is a pharmaceutical company focused on Dermatology, Neurology, Gastroenterology. Key products include INGREZZA SPRINKLE.
FDA Novel Drug Designations
(2017-2024)See 2 novel approvals →
NEUROCRINE at a Glance
- Fast trial execution (15 months median completion)
NEUROCRINE's Key Drugs
NEUROCRINE's core commercial portfolio centers on INGREZZA SPRINKLE, INGREZZA, CRENESSITY, spanning Dermatology and Neurology — its most strategically important drugs approved in the last 15 years.
NEUROCRINE's Recent FDA Approvals
NEUROCRINE secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
NEUROCRINE's Therapeutic Areas
NEUROCRINE's approved drugs and pipeline span 3 therapeutic areas, led by Dermatology and Neurology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NEUROCRINE's Top Competitors
NEUROCRINE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NEUROCRINE Pipeline Snapshot
NEUROCRINE has 20 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 7 Phase 2 and 9 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/20 completed
- • Speed: 15 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2017-04-11
- Latest
- 2026-04-08
- Applications
- 4
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges